4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arcus Biosciences, Inc. (RCUS) operates in the Biotechnology industry and is headquartered in Hayward, United States with about 601 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, RCUS reported $247M in revenue and ($353M) in net income.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Interactive charts & full statements → Open the RCUS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $247M | $258M | $117M | $112M | — |
| Operating Income (EBIT) | ($386M) | ($310M) | ($340M) | ($280M) | — |
| Net Income | ($353M) | ($283M) | ($307M) | ($267M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $17M | $33M | $26M | $160M | $28M | — |
| Operating Income (EBIT) | ($134M) | ($114M) | ($142M) | ($8M) | ($122M) | — |
| Net Income | ($128M) | ($106M) | ($135M) | $0M | ($112M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.1B | $1.1B | $1.1B | $1.3B | — |
| Total Liabilities | $508M | $665M | $633M | $688M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RCUS viewer.
About TickerBase · Data methodology & sources